Search

Your search keyword '"Anna Claudia Pellicelli"' showing total 41 results

Search Constraints

Start Over You searched for: Author "Anna Claudia Pellicelli" Remove constraint Author: "Anna Claudia Pellicelli"
41 results on '"Anna Claudia Pellicelli"'

Search Results

4. Somebody is hiding something: Disentangling interpersonal level drivers and consequences of knowledge hiding in international entrepreneurial firms

5. Cultural Heritage Tradition and Innovation in the Internationalization of Family Business: A Case Study from the Italian Fashion Industry

6. Over the mask of innovation management in the world of Big Data

7. Testing the antecedents of customer knowledge sharing on social media: a quantitative analysis on Italian consumers

8. 'Openness' of public governments in smart cities: removing the barriers for innovation and entrepreneurship

9. Exploring e-Loyalty Antecedents in B2C e-Commerce

10. Private Label and Brand Equity. Opportunities in New Trends

11. Context-specific micro-foundations and successful SME internationalisation in emerging markets: A mixed-method analysis of managerial resources and dynamic capabilities

12. The Impact of Customer Education on the Perception of Made in Italy Products in the Agri-Food Sector

16. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C

17. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

18. Product Risks and Life Cycle

19. The interplay among entrepreneur, employees, and firm level factors in explaining SMEs openness: A qualitative micro-foundational approach

20. Real-world data on the treatment of primary biliary cholangitis with obeticholic acid in Italy: the CLEO-AIGO OCA cohort

21. The role of big data in shaping ambidextrous business process management: case studies from the service industry

22. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance

23. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

24. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life

25. Comparison of resistance profiles among DAA-naive and DAA-experienced patients infected with HCV non-1 genotype in Italy

27. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy

28. VIROLOGICAL FAILURES TO NEW DIRECT ACTING ANTIVIRALS IN A REAL LIFE SETTING MAY REQUIRE UNCONVENTIONAL REGIMENS FOR RE-TREATMENT

29. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies

30. The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution

31. Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapies

32. Innovation and social responsibility in food ingredients market

33. Treatment failure to first-line direct antiviral (DAA) in HCV-related advanced liver disease: An Italian real-life urban setting

34. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents

35. Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for re-treatment

36. Natural HCV resistance is common in Italy and differently associated to genotypes

37. Daclatasvir/sofosbuvir and ribavirin 800mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience

38. Innovation Policy and Environmental Sustainability as Strategic Tools for Reaching Higher Performances A Regional Empirical Analysis to Find the Best Practice

39. Failure to First-Line Direct Antiviral (DAA) Treatment of HCV Infection in an Italian Real-Life Urban Setting

40. P1235 BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS

41. Early viral dynamics in HCV-RNA decay and NS3-resistance development predict the risk of failure to first-generation protease inhibitors

Catalog

Books, media, physical & digital resources